Detailed explanation of the therapeutic effects of Capmatinib (Touradida) and patient medication precautions

Capmatinib (Capmatinib) is an oral small molecule tyrosine kinase inhibitor (TKI) that specifically targets MET exon 14 skipping mutation (MET Exon14 skipping mutation ) of patients with non-small cell lung cancer (NSCLC). MET gene mutations can lead to abnormal proliferation and survival of tumor cells, and capmatinib selectively inhibits MET tyrosine kinase activity, thereby blocking tumor signaling pathways and delaying disease progression. Since MET Exon14 mutations account for a small proportion of patients with advanced NSCLC, capmatinib fills the gap in targeted therapy for this special mutation and provides a precise treatment option for these patients.

Clinical studies have shown that capmatinib shows significant efficacy in lung cancer patients with MET Exon14 mutation-positive lung cancer. In patients who did not receive first-line chemotherapy, the objective response rate (ORR) was about 68%, while in patients who had received prior chemotherapy, the ORR was about 41%, showing an effect across different treatment settings. In addition, capmatinib has also shown certain efficacy in patients with brain metastases. In some patients, brain lesions have shrunk or stabilized, suggesting that the drug can partially cross the blood-brain barrier to exert its effect. Overall, capmatinib can significantly prolong progression-free survival (PFS), improve patients' quality of life and exercise capacity, and reduce the burden of symptoms caused by tumor progression.

During the use of capmatinib, patients must strictly follow the doctor's instructions to take the medication. This medicine is an oral capsule. The general dosage is 400mg each time, twice / days. The capsule should be swallowed whole and should not be chewed or crushed. It is best to take the medicine with a meal or on an empty stomach, but it is necessary to maintain a fixed taking time to ensure stable blood concentration. If a dose is missed, it should be taken as soon as possible, but if it is close to the next dose, the missed dose should be skipped to avoid side effects caused by taking multiple doses at one time. During long-term medication, liver function, kidney function and blood routine monitoring should be carried out regularly, and changes in blood pressure and heart rate should be paid attention to.

Common side effects of capmatinib include edema, nausea, vomiting, fatigue, decreased platelets, and abnormal liver function indicators. Patients should closely observe their physical reactions while taking the medicine. If there is obvious edema or difficulty breathing, they should inform their doctor in time. If they experience persistent nausea or loss of appetite, they can take symptomatic treatment or adjust their diet under the guidance of a doctor. Patients should avoid stopping the medication or increasing or decreasing the dose on their own to avoid affecting the efficacy or increasing the risks. At the same time, patients should maintain healthy living habits while taking the drug, including a balanced diet, moderate exercise, regular work and rest, and avoiding overexertion or mental stress, which will help improve drug efficacy and tolerance.

In short, capmatinib provides a precise targeted treatment option for patients with MET Exon14 mutation-positive non-small cell lung cancer, with clear clinical efficacy and ability to improve quality of life. However, in order to obtain the best curative effect, patients must strictly follow the doctor's instructions to take the medication, and closely monitor adverse reactions during treatment, combined with daily life management and regular review to ensure the safety and effectiveness of the medication. Through scientific management and standardized treatment, capmatinib can help patients delay disease progression and improve treatment compliance and living standards.

Reference link:https://www.drugs.com